CDK4 and neoplasm: This evidence suggests that QN-302 represents a promising therapeutic tool to favour reactivation of p53 in tumours with wild-type TP53 [45] and provides the rationale for further analyses, such as the design of drug combinations with standard chemotherapeutic drugs (i.e. doxorubicin) or other target-specific agents, such as CDK4 inhibitors [7] as well as in vivo treatment optimization (e.g. dose escalation, schedule, and route of administration) to be tested in additional DDLPS PDX models when available.